Form 4: PTC Therapeutics Officer Sells Shares for Tax Obligations
Insider Transaction Report
PTC Therapeutics' SVP, Chief Accounting Officer, Christine Marie Utter, sold shares to cover tax withholding obligations related to RSU vesting.
Summary
- Christine Marie Utter, SVP, Chief Accounting Officer of PTC Therapeutics, Inc. (PTCT), reported two sales of common stock.
- On January 6, 2026, 1,381 shares were sold at a price of $76.95 per share.
- On January 7, 2026, an additional 1,235 shares were sold at a price of $77.45 per share.
- These sales were automatic, executed pursuant to an irrevocable 'sell to cover' election to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
- The first sale related to the vesting of 3,500 RSUs from a January 3, 2025 grant of 14,000 RSUs.
- The second sale related to the vesting of 3,500 RSUs from a January 5, 2023 grant of 14,000 RSUs.
- Following these transactions, Ms. Utter beneficially owns 73,727 shares of common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the reported transactions are routine 'sell to cover' sales for tax withholding purposes related to RSU vesting, executed under a pre-arranged Rule 10b5-1 plan. These are non-discretionary and do not reflect a change in management's outlook or confidence in the company.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Management Comments
- The transactions represent shares automatically sold pursuant to an irrevocable 'sell to cover' election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of RSUs.
Industry Context
This is a routine insider transaction common across all industries, particularly for executives receiving equity compensation in the form of Restricted Stock Units (RSUs). It does not reflect specific industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Minimal impact, as these are routine, non-discretionary sales for tax purposes and do not signal a change in the reporting person's investment thesis or the company's fundamentals.
- Employees: No direct impact beyond the reporting person's compensation structure.
Key Dates
| Date | Description |
|---|---|
| 01/05/2023 | Grant date of 14,000 RSUs, from which 3,500 RSUs vested, leading to a 'sell to cover' transaction. |
| 01/03/2025 | Grant date of 14,000 RSUs, from which 3,500 RSUs vested, leading to a 'sell to cover' transaction. |
| 01/06/2026 | Transaction date for the sale of 1,381 shares of common stock. |
| 01/07/2026 | Transaction date for the sale of 1,235 shares of common stock. |
| 01/08/2026 | Filing date of the Form 4 statement. |
Keywords
PTC Therapeutics, PTCT, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Executive Compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.